Baylor Scott & White Research Institute 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases  3 Products   12 Trials   72 News 
15 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD19 specific CAR T cell therapy / Baylor Scott & White Research Institute
ANCHOR, NCT00840853: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Active, not recruiting
1
68
US
CD19CAR/virus specific T cells, Benadryl and Tylenol, Diphenhydramine and acetaminophen
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
04/16
04/31
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies

Active, not recruiting
1
13
US
CD19.CAR-aNKT cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
06/26
02/35
SAGAN, NCT01853631: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL

Recruiting
1
64
US
Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
12/25
02/36
TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT06090864: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting
1/2
31
US
Chemotherapy, Cell infusion
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Relapse, Refractory
07/26
07/31
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
CERTAIN, NCT04526834: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruiting
1
21
US
CD30.CAR-T, CD30-directed genetically modified autologous T cells
Tessa Therapeutics
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
11/22
03/36
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
1
60
US
CAR T Cells, CD30.CAR T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
04/26
02/40
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, Stand Up To Cancer, National Cancer Institute (NCI)
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT03914885: Compassionate Use Re-Infusion of ATLCAR.CD30

No Longer Available
N/A
US
ATLCAR.CD30, CD30 CAR T cells, Bendamustine, Bendeka, Treanda, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
 
 
high-titer anti-Sars-CoV-2 plasma / Baylor Scott & White Research Institute
NCT04333251: Study Testing Convalescent Plasma vs Best Supportive Care

Not yet recruiting
1
115
NA
high-titer anti-Sars-CoV-2 plasma
Baylor Research Institute
Pneumonia, Interstitial
12/22
12/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD19 specific CAR T cell therapy / Baylor Scott & White Research Institute
ANCHOR, NCT00840853: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Active, not recruiting
1
68
US
CD19CAR/virus specific T cells, Benadryl and Tylenol, Diphenhydramine and acetaminophen
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
04/16
04/31
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies

Active, not recruiting
1
13
US
CD19.CAR-aNKT cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
06/26
02/35
SAGAN, NCT01853631: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL

Recruiting
1
64
US
Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
12/25
02/36
TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT06090864: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting
1/2
31
US
Chemotherapy, Cell infusion
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Relapse, Refractory
07/26
07/31
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
CERTAIN, NCT04526834: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruiting
1
21
US
CD30.CAR-T, CD30-directed genetically modified autologous T cells
Tessa Therapeutics
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
11/22
03/36
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
1
60
US
CAR T Cells, CD30.CAR T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
04/26
02/40
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, Stand Up To Cancer, National Cancer Institute (NCI)
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT03914885: Compassionate Use Re-Infusion of ATLCAR.CD30

No Longer Available
N/A
US
ATLCAR.CD30, CD30 CAR T cells, Bendamustine, Bendeka, Treanda, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
 
 
high-titer anti-Sars-CoV-2 plasma / Baylor Scott & White Research Institute
NCT04333251: Study Testing Convalescent Plasma vs Best Supportive Care

Not yet recruiting
1
115
NA
high-titer anti-Sars-CoV-2 plasma
Baylor Research Institute
Pneumonia, Interstitial
12/22
12/22

Download Options